News CellCentric pockets $220m for blood cancer programme CellCentric has raised $220 million in a Series D financing that will help fund pivotal trials of p300/CBP inhibitor inobrodib in multiple myeloma.
Market Access Anglonordic Life Science 2026: A focus on execution The latest Anglonordic Life Science Conference on 23rd April exhibited a cautious optimism.
News After rival fails, Cytokinetics could broaden Myqorzo label Cytokinetics' Myqorzo has succeeded where BMS's first-to-market Camzyos failed, with a positive trial in non-obstructive hypertrophic cardiomyopathy.
News Amgen, AZ will pilot FDA's real-time clinical trial plan The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur in real time.
News Boehringer/Zealand dual-acting drug causes 16.6% weight loss Boehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide.
News Intellia files CRISPR drug after historic phase 3 readout Intellia has reported the first-ever phase 3 results with an in vivo gene-editing therapy, CRISPR-based lonvo-z for hereditary angioedema.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.